Precigen (PGEN) Stock Price & Analysis

PGEN$4.54-0.12 -2.58%
BiotechnologyGrowth Stock
Compare
Market cap$1.63BEnterprise value$1.71BRevenue (TTM)$156.94MMarket position—

Score

64
Neutral
Value
57
Quality
34
Growth
100

AI Analysis

Snapshot

Precigen is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 64/100) in Biotechnology. Under the hood: P/E 66.5, plus revenue compounding ~11% annually over recent years. Street targets still imply ~230% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

34
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Precigen, Inc. (PGEN) last printed $4.54. Equity value is $1.63B. Trailing earnings multiple 66.64. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$190.93M$230.98M$160.57M$31.99M$31.99M$14.27M$26.91M$6.22M$3.92M$9.68M

About

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Precigen (PGEN) Stock Price & Analysis

PGEN price $4.54 -0.12 -2.58%

Ticker
PGEN
Price
$4.54
Change
-0.12 -2.58%
Market cap
$1.63B
P/E
66.64
Forward P/E
9.00
Dividend yield
0.00%
Beta
0.98
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
64
Value
57
Quality
34
Growth
100

Stocklytics score rationale: value 57, quality 34, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener